alexa NMR Driven Conformational Design - A Powerful Drug Design Tool
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Thorsten Nowak
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
Clear and detailed understanding of dynamic 3D small molecule in solution and the dynamic interchange of accessible low energy conformations have traditionally been predicted computationally or extrapolated from small molecule crystal structure data. The impact of a new quantitative and precise technology is described that provides detailed information of ligand conformations in solution. When coupled with activity data it gives unprecedented accuracy in describing pharmacophoric information that can deliver high impact, in for example, drug design contexts. The necessary experimental information required to define solution conformation is extracted from one & two-dimensional NMR data of ligand molecules in physiologically relevant solution conditions. In addition to driving drug design, conformational information on ligand molecules can be applied to broad settings in drug discovery enabling the identification of chemical equity independently of general screening approaches to template-hopping and virtual screening. Furthermore, it can significantly impact on small molecule drug design in Lead Generation and Lead Optimisation independently or in conjunction with computational chemistry or structure based drug design approaches. The presentation details the application of the technology and describes the use and impact with a number of case studies in the areas of structure based design and GPCR targeting settings.
Thorsten Nowak completed his PhD from the University of Cambridge (UK) in the areas of aldol methodology and natural product synthesis. In 1996 he joint AstraZeneca where he worked on all stages of drug discovery from target to candidate selection in medicinal chemistry as team leader and project manager. His keen interest in new technologies motivated a career move from big pharma to platform technology business in 2012 when he joint C4X Discovery. In his current role he is responsible for all internal drug discovery projects at C4X Discovery as well as continued development of the technology in the context of application to drug discovery.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version